ActiTrexx

Description

ActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel (ATX-002), which is in phase Ib/II testing to prevent GvHD.

Related

• SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• Captor TherapeuticsCaptor Therapeutics develops therapeutics using targeted protein degradation (TPD) to address high‑unmet‑need diseases such as cancer and…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• TTolerogenixxTolerogenixx develops personalized therapies using proprietary modified immune cell technology to target immune modulation, including…
• BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
• MinervaXMinervaX is developing a prophylactic Group B Streptococcal (GBS) vaccine, AlpN GBS, that works as a clinical-stage immunization product…
• Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
• MogrifyMogrify develops platform technologies for direct cellular reprogramming that analyze transcriptomic, gene regulatory, and epigenetic data…